Design and synthesis of highly active Alzheimer’s β-secretase (BACE1) inhibitors, KMI-420 and KMI-429, with enhanced chemical stability
- 1 January 2005
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 15 (1) , 211-215
- https://doi.org/10.1016/j.bmcl.2004.09.090
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 29 references indexed in Scilit:
- Design of Substrate-Based Inhibitors of Human β-SecretaseJournal of Medicinal Chemistry, 2001
- Structure-Based Design: Potent Inhibitors of Human Brain Memapsin 2 (β-Secretase)Journal of Medicinal Chemistry, 2001
- Structure of the Protease Domain of Memapsin 2 (β-Secretase) Complexed with InhibitorScience, 2000
- Design of Potent Inhibitors for Human Brain Memapsin 2 (β-Secretase)Journal of the American Chemical Society, 2000
- Identification of a Novel Aspartic Protease (Asp 2) as β-SecretaseMolecular and Cellular Neuroscience, 1999
- Synthesis and Angiotensin II Receptor Antagonistic Activities of Benzimidazole Derivatives Bearing Acidic Heterocycles as Novel Tetrazole BioisosteresJournal of Medicinal Chemistry, 1996
- The molecular pathology of Alzheimer's diseaseNeuron, 1991
- KNI-102, a novel tripeptide HIV protease inhibitor containing allophenylnorstatine as a transition-state mimic.CHEMICAL & PHARMACEUTICAL BULLETIN, 1991
- Rational design and synthesis of a novel class of active site-targeted HIV protease inhibitors containing a hydroxymethylcarbonyl isostere. Use of phenylnorstatine or allophenylnorstatine as a transition-state mimic.CHEMICAL & PHARMACEUTICAL BULLETIN, 1991
- LATHYRISM: EVIDENCE FOR ROLE OF THE NEUROEXCITATORY AMINOACID BOAAThe Lancet, 1986